This page is for healthcare professionals treating patients with chronic granulomatous disease.
This page is for HCPs treating patients with CGD.

See the value of comprehensive patient support

CGD nurse educators, like Shannon, provide immense support to patients and help reinforce your efforts.

Watch: Support services from ACTIMMUNE®

SHANNON, CGD nurse educator

Your patients are in good hands

Horizon Patient Services, a HorizonCares program, is dedicated to improving the lives of patients with chronic granulomatous disease (CGD) by providing them and their families with access to a comprehensive network of services and support.

The Horizon Patient Services support team consists of case managers, dedicated nurse educators, and other representatives of Horizon Pharma who work directly with patients and their caregivers. The complimentary services guide patients through every step of their journey—from initiating treatment to determining insurance coverage, connecting with others living with CGD, and establishing habits for lifelong adherence.

Our services are based on 3 key pillars: guide, support, and connect.

Guide icon
A case manager will:
  • Work with your office to secure any insurance authorizations that may be necessary to start or continue ACTIMMUNE®
  • Limit financial barriers to treatment by determining insurance coverage and connecting patients with financial assistance options, if necessary
  • Coordinate with the specialty pharmacy to schedule shipments of ACTIMMUNE®
  • Send patients refill reminders via email and/or text
  • Help patients enroll in a sharps disposal program
  • Make adjustments, as needed, when patients experience life changes, such as moving or losing insurance or employment
Support icon
A dedicated CGD nurse educator will:
  • Serve as the main point of contact for all your patients’ needs related to treatment
  • Assist with disease education, day-to-day questions, and treatment challenges
  • Provide injection training and support
  • Work collaboratively with patients’ healthcare team
Connect icon
Horizon Pharma will:
  • Connect patients and their caregivers with communities of people living with CGD and other rare diseases using social media platforms, peer mentor programs, and live events, where families can share stories, tips, and resources with each other
  • Introduce patients to advocacy groups and other community resources

To learn more, call 1 (877) 305-7704 or visit

Get information about CGD and ACTIMMUNE® (Interferon gamma-1b) sign up button

Important Safety Information


ACTIMMUNE® (Interferon gamma-1b) is indicated:

Important Safety Information


ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis



  • In patients who develop or have known hypersensitivity to interferon-gamma, E coli-derived products, or any component of the product


  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year

  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE

  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known


  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)


  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness